{
    "2020-10-21": [
        [
            {
                "time": "2020-Q3",
                "original_text": "健帆生物：唐先敏合计减持0.21%公司股份 减持股份",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "唐先敏",
                        "减持"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物(300529.SZ)副经理唐先敏减持167.62万股 减持时间已过半 减持股份",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "唐先敏",
                        "减持",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物(300529)：三季报业绩超预期 Q3提速显著 持续引领全球血液灌流渗透率提升",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "三季报",
                        "业绩超预期",
                        "Q3提速",
                        "血液灌流"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物(300529)：Q3利润增长加速 全年业绩可期",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "Q3",
                        "利润增长",
                        "全年业绩"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "【财报智读】健帆生物：2020年前三季度营业总收入13.15亿元，归母净利润6.27亿元",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "财报",
                        "营业总收入",
                        "归母净利润"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物(300529)：三季度业绩加速增长 每周1次灌流治疗写入血液净化操作规程",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "三季度",
                        "业绩加速",
                        "灌流治疗"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物(300529)：收入增速环比继续加速 肾病及肝病业务有望持续快速增长",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "收入增速",
                        "肾病",
                        "肝病",
                        "业务增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物(300529)：Q3持续高增长 海外市场潜力可期",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "Q3",
                        "高增长",
                        "海外市场"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物三季报点评：Q3持续高增长 海外市场潜力可期【东吴医药朱国广团队】",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "三季报",
                        "Q3",
                        "高增长",
                        "海外市场"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-Q3",
                "original_text": "健帆生物公布三季报 前三季净利增加50.13%",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "三季报",
                        "净利增加"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}